{"id":"interleukin","rwe":[],"_fda":{"id":"7e8f9d55-ff6d-cbe7-e053-2a91aa0a382e","set_id":"0fd0dcef-79c6-4489-a533-996aa5331d9c","openfda":{"nui":["N0000185375","N0000175629","N0000184306","N0000185001","M0000728","M0016962","M0516536"],"upc":["0317089296188"],"unii":["2P3VWU3H10","KK0Z92II8M","ML4QRZ1HCL","O80TY208ZW","WQZ3G9PF0H","37CQ2C7X93","T7S323PKJS","7M867G6T1U","YF70189L0N","8R564U2E1P","2S713A4VP3","6EC706HI7F","269XH13919","308LM01C72","2510RH3I89"],"route":["ORAL"],"spl_id":["7e8f9d55-ff6d-cbe7-e053-2a91aa0a382e"],"brand_name":["GUNA-HEMORRHOIDS"],"spl_set_id":["0fd0dcef-79c6-4489-a533-996aa5331d9c"],"package_ndc":["17089-296-18"],"product_ndc":["17089-296"],"generic_name":["ACTIVATED CHARCOAL - ARNICA MONTANA - ATROPA BELLADONNA - CANAKINUMAB - HYDROCOTYLE ASIATICA EXTRACT - AESCULUS HIPPOCASTANUM FLOWER - MELISSA OFFICINALIS - PAEONIA OFFICINALIS ROOT - PODOPHYLLUM PELTATUM ROOT - PORK LIVER - STRYCHNOS NUX-VOMICA SEED - SUS SCROFA SMALL INTESTINE MUCOSA LYMPH FOLLICLE - SUS SCROFA VEIN - HAMAMELIS VIRGINIANA ROOT BARK/STEM BARK - ANTI-INTERLEUKIN-1.ALPHA. IMMUNOGLOBULIN G RABBIT -"],"product_type":["HUMAN OTC DRUG"],"pharm_class_cs":["Allergens [CS]","Plant Proteins [CS]","Seed Storage Proteins [CS]"],"pharm_class_pe":["Increased Histamine Release [PE]","Cell-mediated Immunity [PE]","Increased IgG Production [PE]"],"substance_name":["ACTIVATED CHARCOAL","AESCULUS HIPPOCASTANUM FLOWER","ANTI-INTERLEUKIN-1.ALPHA. IMMUNOGLOBULIN G RABBIT","ARNICA MONTANA","ATROPA BELLADONNA","CANAKINUMAB","HAMAMELIS VIRGINIANA ROOT BARK/STEM BARK","HYDROCOTYLE ASIATICA EXTRACT","MELISSA OFFICINALIS","PAEONIA OFFICINALIS ROOT","PODOPHYLLUM PELTATUM ROOT","PORK LIVER","STRYCHNOS NUX-VOMICA SEED","SUS SCROFA SMALL INTESTINE MUCOSA LYMPH FOLLICLE","SUS SCROFA VEIN"],"pharm_class_epc":["Non-Standardized Plant Allergenic Extract [EPC]"],"manufacturer_name":["Guna spa"],"is_original_packager":[true]},"purpose":["USES Temporary relief of symptoms due to hemorrhoids such as: Pain Itching Burning"],"version":"2","warnings":["WARNINGS Stop use and ask doctor if symptoms persist more than 5 days. If pregnant or breast-feeding ask a health professional before use. Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away. Contains ethyl alcohol 30%"],"questions":["QUESTIONS Questions?: info@gunainc.com, tel. (484) 223-3500"],"effective_time":"20181221","active_ingredient":["ACTIVE INGREDIENTS/PURPOSE AESCULUS HIPPOCASTANUM 6C VENOUS FLOW SUPPORT ANTI INTERLEUKIN 1 ALPHA 4C IMMUNE STRENGTHENING ANTI INTERLEUKIN 1 BETA 4C IMMUNE STRENGTHENING ARNICA MONTANA 6C HEMORRHOIDAL ITCHING BELLADONNA 6C ANTI-INFLAMMATORY CARBO VEGETALIS 10X BOWEL DETOXIFICATION HAMAMELIS VIRGINIANA 6C HEMORRHOIDAL PAIN HEPAR 6X, 12X, 30X SUPPORTS LIVER DETOXIFICATION HYDROCOTYLE ASIATICA 6C PAIN RELIEF LYMPHATIC VESSEL 6X PROMOTES LYMPH FLOW MELISSA OFFICINALIS 6C DIGESTIVE NUX VOMICA 6C DIGESTIVE PAEONIA OFFICINALIS 6X ANTIHEMORRHOIDAL PODOPHYLLUM PELTATUM 4C BOWEL ACTIVITY VEIN 4C VENOUS FLOW SUPPORT"],"inactive_ingredient":["Inactive ingredient: Ethyl alcohol 30%."],"indications_and_usage":["Take 15 minutes before meals."],"dosage_and_administration":["DIRECTIONS Adults and children 12 years and older 20 drops in a little water, 2 times per day Children between 12 years and 6 years of age 10 drops in a little water, 2 times per day Children under 6 years 5 drops in a glass of water, 2 times per day"],"spl_product_data_elements":["GUNA-HEMORRHOIDS activated charcoal - arnica montana - atropa belladonna - canakinumab - hydrocotyle asiatica extract - aesculus hippocastanum flower - melissa officinalis - paeonia officinalis root - podophyllum peltatum root - pork liver - strychnos nux-vomica seed - sus scrofa small intestine mucosa lymph follicle - sus scrofa vein - hamamelis virginiana root bark/stem bark - anti-interleukin-1.alpha. immunoglobulin g rabbit - ALCOHOL AESCULUS HIPPOCASTANUM FLOWER AESCULUS HIPPOCASTANUM FLOWER ANTI-INTERLEUKIN-1.ALPHA. IMMUNOGLOBULIN G RABBIT ANTI-INTERLEUKIN-1.ALPHA. IMMUNOGLOBULIN G RABBIT CANAKINUMAB CANAKINUMAB ARNICA MONTANA ARNICA MONTANA ATROPA BELLADONNA ATROPA BELLADONNA ACTIVATED CHARCOAL ACTIVATED CHARCOAL HAMAMELIS VIRGINIANA ROOT BARK/STEM BARK HAMAMELIS VIRGINIANA ROOT BARK/STEM BARK PORK LIVER PORK LIVER HYDROCOTYLE ASIATICA EXTRACT HYDROCOTYLE ASIATICA EXTRACT SUS SCROFA SMALL INTESTINE MUCOSA LYMPH FOLLICLE SUS SCROFA SMALL INTESTINE MUCOSA LYMPH FOLLICLE MELISSA OFFICINALIS MELISSA OFFICINALIS STRYCHNOS NUX-VOMICA SEED STRYCHNOS NUX-VOMICA SEED PAEONIA OFFICINALIS ROOT PAEONIA OFFICINALIS ROOT PODOPHYLLUM PELTATUM ROOT PODOPHYLLUM PELTATUM ROOT SUS SCROFA VEIN SUS SCROFA VEIN"],"pregnancy_or_breast_feeding":["PREGNANCY If pregnant or breast-feeding ask a doctor before use."],"keep_out_of_reach_of_children":["WARNINGS Keep out of reach of children."],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL 5USHEM-Rev03-02-05-18"]},"tags":[],"safety":{"boxedWarnings":[]},"trials":[],"_chembl":{"chemblId":"CHEMBL4297771","moleculeType":"Unknown"},"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Interleukin","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T02:17:35.846846+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T02:17:41.371117+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Interleukin","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T02:17:41.842540+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T02:17:34.736672+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T02:17:34.736710+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T02:17:34.736715+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4297771/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:17:42.720704+00:00"}},"offLabel":[],"timeline":[],"_dailymed":{"setId":"23886c49-5992-4a59-af52-e24eb3c9fbc5","title":"CITOMIX (ALDESLEUKIN - BINETRAKIN - CANAKINUMAB - CENTELLA ASIATICA - CRANBERRY - HUMAN INTERLEUKIN-6 (NONGLYCOSYLATED) - INTERFERON GAMMA-1B - LENOGRASTIM - PINEAPPLE - SUS SCROFA BONE MARROW - SUS SCROFA SMALL INTESTINE MUCOSA LYMPH FOLLICLE - SUS SCROFA THYMUS -) PELLET [GUNA SPA]"},"ecosystem":[],"mechanism":{"drugClass":"Non-Standardized Plant Allergenic Extract [EPC]"},"_scrapedAt":"2026-03-28T05:09:49.211Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T02:17:44.694254+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT01468896","phase":"PHASE1, PHASE2","title":"Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-10-26","conditions":"Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Unresectable Head and Neck Squamous Cell Carcinoma","enrollment":23},{"nctId":"NCT01038778","phase":"PHASE1, PHASE2","title":"Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-10-29","conditions":"Clear Cell Renal Cell Carcinoma, Metastatic Kidney Carcinoma, Stage III Renal Cell Cancer AJCC v7","enrollment":47},{"nctId":"NCT03721068","phase":"PHASE1","title":"Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma","status":"RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2019-02-19","conditions":"Neuroblastoma, Osteosarcoma","enrollment":18},{"nctId":"NCT03030378","phase":"PHASE1","title":"Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-05-30","conditions":"Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm","enrollment":36},{"nctId":"NCT04729959","phase":"PHASE2","title":"Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-03-11","conditions":"Diffuse Astrocytoma, IDH-Wildtype, Recurrent Glioblastoma","enrollment":59},{"nctId":"NCT07493317","phase":"PHASE2","title":"Neutralizing Interleukin (IL)-6","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2026-03","conditions":"Major Depressive Disorder","enrollment":60},{"nctId":"NCT06767046","phase":"PHASE1","title":"KRAS-Specific Autologous TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Corregene Biotechnology Co., Ltd","startDate":"2025-02-18","conditions":"Colorectal, Pancreatic, Non-small Cell Lung Cancer (NSCLC)","enrollment":8},{"nctId":"NCT02557074","phase":"PHASE3","title":"TREg Activation in the Treatment of the PELADE (Alopecia Areata)","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2015-12-15","conditions":"Alopecia Areata","enrollment":44},{"nctId":"NCT00338377","phase":"PHASE2","title":"Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-02-01","conditions":"Melanoma","enrollment":1230},{"nctId":"NCT06743126","phase":"PHASE3","title":"SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma","status":"RECRUITING","sponsor":"Immatics US, Inc.","startDate":"2025-01-14","conditions":"Melanoma, Cutaneous Malignant","enrollment":360},{"nctId":"NCT04629729","phase":"PHASE1","title":"FT819 in Subjects With B-cell Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fate Therapeutics","startDate":"2021-07-12","conditions":"Lymphoma, B-Cell, Chronic Lymphocytic Leukemia, Precursor B-Cell Acute Lymphoblastic Leukemia","enrollment":54},{"nctId":"NCT06152809","phase":"PHASE1","title":"CIML NK Cells With Venetoclax for AML","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-02-20","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Recurrent, Leukemia","enrollment":10},{"nctId":"NCT06910475","phase":"NA","title":"Physical Exercise and Biomolecular Analysis to Reduce Uremic Toxins in Chronic Kidney Disease: An Exploratory Study","status":"ENROLLING_BY_INVITATION","sponsor":"Catholic University of Brasília","startDate":"2025-04-01","conditions":"Kidney Disease, Chronic, Kidney Failure Chronic","enrollment":1600},{"nctId":"NCT07234838","phase":"","title":"Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYPSO)","status":"RECRUITING","sponsor":"Jonathan Krygier","startDate":"2026-02-01","conditions":"Psoriasis, Condyloma Acuminata, Biotherapies","enrollment":600},{"nctId":"NCT04119024","phase":"PHASE1","title":"Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Anusha Kalbasi","startDate":"2025-10-07","conditions":"Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8","enrollment":18},{"nctId":"NCT04347616","phase":"PHASE1, PHASE2","title":"Natural Killer-cell Therapy for Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"Radboud University Medical Center","startDate":"2020-12-03","conditions":"Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, Relapsed, Adult","enrollment":9},{"nctId":"NCT05267821","phase":"PHASE2, PHASE3","title":"Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODS","status":"RECRUITING","sponsor":"Nationwide Children's Hospital","startDate":"2022-06-14","conditions":"Pediatric Sepsis-induced Multiple Organ Dysfunction Syndrome (MODS)","enrollment":500},{"nctId":"NCT06946680","phase":"PHASE1","title":"IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Pediatric High-grade Glioma (HGG)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2025-03-18","conditions":"High-grade Glioma","enrollment":18},{"nctId":"NCT06052618","phase":"PHASE2","title":"Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-03-17","conditions":"KSHV Inflammatory Cytokine Syndrome (KICS), Kaposi Sarcoma Herpesvirus -Associated Multicentric Castleman Disease","enrollment":75},{"nctId":"NCT06718049","phase":"","title":"Role of Interleukin 18 (IL-18) and Interleukin 18 Binding Protein (IL-18BP) in the Diagnostic Work-up of Systemic Juvenile Idiopathic Arthritis and Autoinflammatory Diseases: Possible Biomarkers in the Differential Diagnosis of Other Febrile Diseases","status":"NOT_YET_RECRUITING","sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","startDate":"2027-01-01","conditions":"Systemic Juvenile Idiopathic Arthritis (sJIA)","enrollment":9},{"nctId":"NCT06826547","phase":"EARLY_PHASE1","title":"Optimization of Basal Insulin During Ramadan Fasting in Type 2 Diabetic Patients: Comparison Between DAR Recommendations and the Carbohydrate Fasting Test & Metabolic and Inflammatory Consequences","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Tunis El Manar","startDate":"2025-02-15","conditions":"Diabetes Mellitus, Type 2 Treated With Insulin, Fasting, Intermittent, Ramadan Fasting","enrollment":100},{"nctId":"NCT05353530","phase":"PHASE1","title":"IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Adult Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2023-07-25","conditions":"Glioblastoma Multiforme, Glioblastoma","enrollment":39},{"nctId":"NCT06557265","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)","status":"RECRUITING","sponsor":"Nkarta, Inc.","startDate":"2024-06-13","conditions":"Lupus Nephritis, Primary Membranous Nephropathy","enrollment":96},{"nctId":"NCT04332653","phase":"PHASE1, PHASE2","title":"NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors","status":"COMPLETED","sponsor":"NeoImmuneTech","startDate":"2020-06-10","conditions":"Any Advanced Solid Tumors, Triple Negative Breast Cancer, Non Small Cell Lung Cancer","enrollment":215},{"nctId":"NCT02858310","phase":"PHASE1, PHASE2","title":"E7 TCR T Cells for Human Papillomavirus-Associated Cancers","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-01-27","conditions":"Papillomavirus Infections, Cervical Intraepithelial Neoplasia, Carcinoma In Situ","enrollment":224},{"nctId":"NCT05600920","phase":"PHASE1, PHASE2","title":"A Single-arm, Dose-escalation Trial of Long-acting Recombinant Human IL-7 (NT-I7, Efineptakin Alfa) for Idiopathic CD4 Lymphopenia","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-11-06","conditions":"Idiopathic CD4 Lymphopenia","enrollment":60},{"nctId":"NCT04940299","phase":"PHASE2","title":"Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-09-23","conditions":"Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Bladder Carcinoma","enrollment":35},{"nctId":"NCT00026312","phase":"PHASE3","title":"Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2001-10-26","conditions":"Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Recurrent Neuroblastoma","enrollment":1449},{"nctId":"NCT06710197","phase":"PHASE2","title":"IL-1 Inhibition in Early TNBC","status":"WITHDRAWN","sponsor":"University Health Network, Toronto","startDate":"2025-03-05","conditions":"Early Stage Triple Negative ER Low Breast Cancer","enrollment":""},{"nctId":"NCT06321484","phase":"PHASE1","title":"Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-10-09","conditions":"Platinum-resistant Ovarian Cancer, Recurrent Ovary Cancer, Ovarian Cancer","enrollment":18},{"nctId":"NCT06724562","phase":"","title":"IL1 Inhibition in FOP","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2025-04-01","conditions":"Fibrodysplasia Ossificans Progressiva (FOP)","enrollment":11},{"nctId":"NCT07443020","phase":"PHASE1","title":"Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary Tumors","status":"NOT_YET_RECRUITING","sponsor":"Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)","startDate":"2026-03","conditions":"Malignant Pleural Effusion, Malignant Mesothelioma, Pleural Effusion, Malignant","enrollment":10},{"nctId":"NCT06239220","phase":"PHASE2","title":"PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC","status":"RECRUITING","sponsor":"Glenn J. Hanna","startDate":"2024-02-16","conditions":"Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer","enrollment":25},{"nctId":"NCT04205838","phase":"PHASE2","title":"Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma","status":"TERMINATED","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2020-03-04","conditions":"Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma, Progressive Disease","enrollment":23},{"nctId":"NCT04747847","phase":"EARLY_PHASE1","title":"Pilot Study of Atorvastatin and Anakinra in Children With Coronary Artery Abnormalities Secondary to Kawasaki Disease","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2019-06-22","conditions":"Kawasaki Disease","enrollment":5},{"nctId":"NCT04426669","phase":"PHASE1, PHASE2","title":"A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering","status":"COMPLETED","sponsor":"Intima Bioscience, Inc.","startDate":"2020-05-15","conditions":"Gastrointestinal Epithelial Cancer, Gastrointestinal Neoplasms, Cancer of Gastrointestinal Tract","enrollment":23},{"nctId":"NCT05566223","phase":"PHASE1, PHASE2","title":"CISH Inactivated TILs in the Treatment of NSCLC","status":"WITHDRAWN","sponsor":"Intima Bioscience, Inc.","startDate":"2023-02","conditions":"Carcinoma, Non-Small-Cell Lung, Metastatic Non Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer","enrollment":""},{"nctId":"NCT02340676","phase":"PHASE2","title":"A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory cGVHD","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2015-02","conditions":"Chronic Graft-versus-host-disease","enrollment":25},{"nctId":"NCT07423975","phase":"PHASE2","title":"Advancing Reperfusion Therapy for Ischemic Stroke: Safety and Efficacy of Anakinra for Futile Reperfusion Following Endovascular Treatment in Patients With Acute Ischemic Stroke","status":"NOT_YET_RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2026-03-01","conditions":"Stroke Acute, Endovascular Treatment","enrollment":159},{"nctId":"NCT04052334","phase":"PHASE1","title":"Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2019-09-27","conditions":"Sarcoma","enrollment":9},{"nctId":"NCT05174507","phase":"PHASE2","title":"Empagliflozin and Anakinra for the Treatment of Postprandial Hypoglycemia in Patients With Prediabetes","status":"WITHDRAWN","sponsor":"University Hospital, Basel, Switzerland","startDate":"2022-06-24","conditions":"Postprandial Hypoglycemia","enrollment":""},{"nctId":"NCT01366092","phase":"PHASE2","title":"Daily IL-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2011-07","conditions":"Chronic Graft-versus-host Disease","enrollment":35},{"nctId":"NCT01659151","phase":"PHASE2","title":"Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2012-08-03","conditions":"Metastatic Melanoma","enrollment":17},{"nctId":"NCT07389239","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies.","status":"NOT_YET_RECRUITING","sponsor":"University of Chicago","startDate":"2026-06-23","conditions":"Ovarian Cancer, Advanced Malignant Solid Tumor","enrollment":24},{"nctId":"NCT00339157","phase":"PHASE2, PHASE3","title":"Interleukin-1 Receptor Antagonist (IL-1RA) (ANAKINRA) IN SEVERE SYSTEMIC-ONSET JUVENILE IDIOPATHIC ARTHRITIS","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2006-05-11","conditions":"Systemic-Onset Juvenile Idiopathic Arthritis","enrollment":24},{"nctId":"NCT02021422","phase":"PHASE1","title":"A Pilot, Prospective, Non-randomized Evaluation of the Safety of Anakinra Plus Standard Chemotherapy","status":"COMPLETED","sponsor":"Baylor Research Institute","startDate":"2013-12","conditions":"Pancreas Cancer","enrollment":13},{"nctId":"NCT07410494","phase":"PHASE1, PHASE2","title":"Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors","status":"RECRUITING","sponsor":"Essen Biotech","startDate":"2026-02-01","conditions":"Cancer, Breast Cancer, Non-Small Cell Lung Cancer (NSCLC)","enrollment":85},{"nctId":"NCT06713174","phase":"NA","title":"Interleukin 8 and10 Levels Changes in Teeth With Necrotic Pulp and Apical Periodontitis","status":"COMPLETED","sponsor":"Faculty of Dental Medicine for Girls","startDate":"2024-12-15","conditions":"Pulp and Periapical Tissue Disease, Patients With Pulp Necrosis and Apical Periodontitis","enrollment":22},{"nctId":"NCT07410676","phase":"PHASE1, PHASE2","title":"EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Essen Biotech","startDate":"2026-02-01","conditions":"Cancer, Sarcoma, Leukaemia","enrollment":83},{"nctId":"NCT06237881","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-01-31","conditions":"Advanced Solid Tumor, Melanoma, Lung Neoplasms","enrollment":15},{"nctId":"NCT05964465","phase":"PHASE4","title":"Mechanisms of Smell Improvement With Dupilumab.","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2023-08-10","conditions":"Chronic Rhinosinusitis With Nasal Polyps","enrollment":60},{"nctId":"NCT06974877","phase":"PHASE1","title":"Repeat PET/CT Imaging in People With CAPS and Anakinra-Induced Amyloidosis Using an Amyloid-Reactive Peptide to Measure Changes in Organ-Specific Amyloid Load","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-09-10","conditions":"Cryopyrin-Associated Periodic Syndromes, Amyloidosis","enrollment":30},{"nctId":"NCT05391750","phase":"PHASE1","title":"Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2022-10-19","conditions":"Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma","enrollment":7},{"nctId":"NCT01875601","phase":"PHASE1","title":"NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2013-06-11","conditions":"Solid Tumors, Brain Tumors, Sarcoma","enrollment":16},{"nctId":"NCT07288073","phase":"PHASE2","title":"TIL Therapy in cSCC and MCC","status":"RECRUITING","sponsor":"Karam Khaddour, MD, MS","startDate":"2026-02-10","conditions":"Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma","enrollment":14},{"nctId":"NCT07410312","phase":"EARLY_PHASE1","title":"BRIDGE - Blocking Receptor of IL-1β for Donor Graft Edema Reduction","status":"NOT_YET_RECRUITING","sponsor":"Northwestern University","startDate":"2026-02-01","conditions":"Lung Transplant Recipient","enrollment":20},{"nctId":"NCT06158828","phase":"PHASE1, PHASE2","title":"Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2024-05-15","conditions":"AML, Childhood, Aml, Acute Myeloid Leukemia, Pediatric","enrollment":68},{"nctId":"NCT06325748","phase":"PHASE1","title":"SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS","status":"ACTIVE_NOT_RECRUITING","sponsor":"Senti Biosciences","startDate":"2024-04-22","conditions":"AML/MDS, CD33 Expressing Hematological Malignancies, FLT3 Expressing Hematological Malignancies","enrollment":21},{"nctId":"NCT05493566","phase":"EARLY_PHASE1","title":"Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Emory University","startDate":"2022-11-01","conditions":"Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8","enrollment":15},{"nctId":"NCT07052305","phase":"PHASE1","title":"NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2026-02-10","conditions":"Large B-cell Lymphoma","enrollment":24},{"nctId":"NCT03761108","phase":"PHASE1, PHASE2","title":"Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2019-01-23","conditions":"Multiple Myeloma","enrollment":387},{"nctId":"NCT03511118","phase":"","title":"Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants","status":"RECRUITING","sponsor":"Duke University","startDate":"2018-10-04","conditions":"Lactating Women on Select DOI, Breastfed Infants of Mothers on Select DOI","enrollment":1600},{"nctId":"NCT06598371","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-11-21","conditions":"Select Advanced Solid Tumors","enrollment":141},{"nctId":"NCT06287528","phase":"PHASE1","title":"A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-02-23","conditions":"Philadelphia-Negative ALL, Philadelphia-Positive ALL, Relapsed ALL, Adult","enrollment":18},{"nctId":"NCT02964078","phase":"PHASE2","title":"Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2017-04-25","conditions":"Kidney Cancer","enrollment":27},{"nctId":"NCT07396194","phase":"","title":"Ankylosing Spondylitis","status":"NOT_YET_RECRUITING","sponsor":"Sohag University","startDate":"2026-03-01","conditions":"Ankylosing Spondylitis","enrollment":84},{"nctId":"NCT07393490","phase":"NA","title":"Effect of Apneic Oxygenation of the Non-ventilated Lung During Lung Cancer Surgery.","status":"RECRUITING","sponsor":"Osijek University Hospital","startDate":"2025-01-02","conditions":"Lung Cancer (Diagnosis)","enrollment":56},{"nctId":"NCT07394322","phase":"NA","title":"Interleukin-6 in the Development of Meconium Aspiration Syndrome in Newborn","status":"COMPLETED","sponsor":"Benha University","startDate":"2023-01-01","conditions":"Meconium Aspiration Syndrome","enrollment":120},{"nctId":"NCT01937468","phase":"PHASE1","title":"Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2013-11","conditions":"Chronic Graft Versus Host Disease, Chronic GVHD, Complications of Organ Transplant Stem Cells","enrollment":25},{"nctId":"NCT05316116","phase":"EARLY_PHASE1","title":"Siltuximab in Large Granular Lymphocytic Leukemia (LGLL)","status":"TERMINATED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2023-02-15","conditions":"Large Granular Lymphocyte Leukemia","enrollment":6},{"nctId":"NCT04844814","phase":"PHASE2","title":"Anakinra vs Prednisone to Treat Gout Flare in Patients With Chronic Kidney Disease Stage 4/5 or Renal Transplantation","status":"SUSPENDED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-06-02","conditions":"Gout, Chronic Kidney Disease, Renal Transplantation","enrollment":204},{"nctId":"NCT04263831","phase":"PHASE1, PHASE2","title":"Low Dose IL-2 for the Treatment of Crohn's Disease","status":"RECRUITING","sponsor":"Boston Children's Hospital","startDate":"2021-03-11","conditions":"Crohn Disease","enrollment":30},{"nctId":"NCT05676827","phase":"","title":"Pain, Central Sensitization and Psychoemotional State in Patients With Chronic Masticatory Muscle Pain","status":"ENROLLING_BY_INVITATION","sponsor":"Wroclaw Medical University","startDate":"2023-09-01","conditions":"TMD, Masticatory Muscle Pain","enrollment":102},{"nctId":"NCT03666000","phase":"PHASE1","title":"Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)","status":"RECRUITING","sponsor":"Imugene Limited","startDate":"2019-03-11","conditions":"Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia","enrollment":135},{"nctId":"NCT07060638","phase":"PHASE2","title":"Integrated Therapies for Alcohol Use in Alcohol-associated Liver Disease (ITAALD) Trial","status":"RECRUITING","sponsor":"Samer Gawrieh","startDate":"2026-01-27","conditions":"Alcohol-associated Hepatitis","enrollment":216},{"nctId":"NCT04562129","phase":"PHASE2","title":"IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2020-09-24","conditions":"Melanoma Stage III, Melanoma Stage IV, Inoperable Disease","enrollment":29},{"nctId":"NCT06318871","phase":"EARLY_PHASE1","title":"Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-08-28","conditions":"Renal Carcinoma, Renal Cell Carcinoma, Urothelial Carcinoma","enrollment":10},{"nctId":"NCT03474497","phase":"PHASE1, PHASE2","title":"UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade","status":"ACTIVE_NOT_RECRUITING","sponsor":"Megan Daly, MD","startDate":"2019-05-20","conditions":"Non Small Cell Lung Cancer, Metastatic Melanoma, Metastatic Renal Cell Carcinoma","enrollment":18},{"nctId":"NCT07371689","phase":"PHASE3","title":"ANAKINRA IN THE TREATMENT OF PEDIATRIC ACUTE MYOCARDITIS","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-02","conditions":"PEDIATRIC ACUTE MYOCARDITIS","enrollment":110},{"nctId":"NCT05091385","phase":"","title":"Efficacy of Mepolizumab in Polish Patients With Severe Eosinophilic Asthma","status":"COMPLETED","sponsor":"Medical University of Lodz","startDate":"2022-01-01","conditions":"Asthma; Eosinophilic","enrollment":106},{"nctId":"NCT05309616","phase":"PHASE2","title":"Effects of Interleukin (IL)-17A Inhibition on Idiopathic Subglottic Stenosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yale University","startDate":"2025-02-20","conditions":"Idiopathic Subglottic Stenosis","enrollment":10},{"nctId":"NCT06381661","phase":"PHASE2","title":"Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-05-01","conditions":"Sepsis","enrollment":2000},{"nctId":"NCT03968913","phase":"EARLY_PHASE1","title":"Biologic Therapy to Prevent Osteoarthritis After ACL Injury","status":"RECRUITING","sponsor":"University of California, Los Angeles","startDate":"2021-09-15","conditions":"Anterior Cruciate Ligament Injuries","enrollment":32},{"nctId":"NCT05357027","phase":"PHASE1, PHASE2","title":"HPV16 E6 TCR T Cells for Cervical Carcinoma","status":"TERMINATED","sponsor":"TCRCure Biopharma Ltd.","startDate":"2022-08-10","conditions":"Cervical Carcinoma","enrollment":5},{"nctId":"NCT06736379","phase":"PHASE1","title":"Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer","status":"RECRUITING","sponsor":"VLP Therapeutics","startDate":"2025-05-13","conditions":"Head and Neck Cancers- Squamous Cell, Head and Neck Cancer, Solid Tumors","enrollment":41},{"nctId":"NCT07192900","phase":"PHASE1","title":"Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease","status":"RECRUITING","sponsor":"David Bartlett, MD","startDate":"2026-03","conditions":"Malignant Pleural Effusion, Malignant Mesothelioma, Pleural Effusion, Malignant","enrollment":10},{"nctId":"NCT07343934","phase":"PHASE1","title":"huCART19-IL18-eDHFR Cells in Relapsed/Refractory Follicular Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2026-02","conditions":"Relapsed or Refractory Follicular Lymphoma","enrollment":6},{"nctId":"NCT02586831","phase":"PHASE1, PHASE2","title":"Diabetes Islet Preservation Immune Treatment","status":"WITHDRAWN","sponsor":"Camillo Ricordi and Jay Skyler","startDate":"2024-06-01","conditions":"Diabetes Mellitus, Type 1, Hypoglycemia, Autoimmune Diseases","enrollment":""},{"nctId":"NCT05989828","phase":"PHASE1","title":"A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer","status":"SUSPENDED","sponsor":"University of Southern California","startDate":"2024-12-17","conditions":"Triple Negative Breast Cancer","enrollment":20},{"nctId":"NCT05177822","phase":"PHASE2","title":"Interleukin-1 Blockade in Acute Myocardial Infarction to Prevent Heart Failure","status":"RECRUITING","sponsor":"Virginia Commonwealth University","startDate":"2022-05-24","conditions":"Heart Failure","enrollment":84},{"nctId":"NCT06807177","phase":"","title":"Can Blood Biomarkers of Inflammation and BDNF be Used to Assess the Effectiveness of Collagen Mesotherapy in Chronic CMPS?","status":"ENROLLING_BY_INVITATION","sponsor":"National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland","startDate":"2025-01-08","conditions":"Myofascial Pain Syndrome - Neck, Spondyloarthrosis, Neck Pain","enrollment":40},{"nctId":"NCT07333105","phase":"NA","title":"Whole Body Vibration Versus Aerobic Training on Interleukin 6 and Endurance After Renal Transplantation","status":"COMPLETED","sponsor":"Cairo University","startDate":"2023-09-01","conditions":"Whole Body Vibration, Aerobic Training, Interleukin 6","enrollment":60},{"nctId":"NCT02739412","phase":"PHASE2","title":"Efficacy of Low Dose, SubQ Interleukin-2 (IL-2) to Expand Endogenous Regulatory T-Cells in Liver Transplant Recipients","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2016-11","conditions":"Liver Transplantation","enrollment":6},{"nctId":"NCT07329998","phase":"NA","title":"The Aim of the Study is to Check Whether Follicular Fluid Evaluation Using a Spectrophotometer Can Differentiate High Quality Oocytes From Low Quality Oocytes. Oocyte Quality Will be Defined Using GDF9, BMP15 and Oocyte Morphology.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hillel Yaffe Medical Center","startDate":"2024-09-22","conditions":"Oocyte Quality Assessment Using Spectrophotometer","enrollment":200},{"nctId":"NCT05926505","phase":"PHASE2, PHASE3","title":"Safety and Efficacy of Anakinra Treatment for Patients With Post Acute Covid Syndrome","status":"RECRUITING","sponsor":"Hellenic Institute for the Study of Sepsis","startDate":"2023-09-06","conditions":"Post-Acute COVID-19 Syndrome, Post-Acute COVID-19, Long COVID","enrollment":182},{"nctId":"NCT06946225","phase":"PHASE1","title":"ACTengine® IMA203 Combined With mRNA-4203","status":"RECRUITING","sponsor":"Immatics US, Inc.","startDate":"2025-07-25","conditions":"Cutaneous Melanoma, Synovial Sarcoma","enrollment":15},{"nctId":"NCT06255028","phase":"PHASE1","title":"A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Century Therapeutics, Inc.","startDate":"2025-02-06","conditions":"Systemic Lupus Erythematosus, Lupus Nephritis, Idiopathic Inflammatory Myopathies","enrollment":6},{"nctId":"NCT05902520","phase":"PHASE1","title":"Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"AgonOx, Inc.","startDate":"2023-06-19","conditions":"HNSCC, Melanoma, Gynecologic Cancer","enrollment":18},{"nctId":"NCT06236425","phase":"PHASE1","title":"TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2024-03-14","conditions":"Squamous Cell Carcinoma of Head and Neck, Metastatic Squamous Cell Carcinoma","enrollment":7},{"nctId":"NCT05628883","phase":"PHASE1","title":"Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2022-11-22","conditions":"Metastatic Melanoma, Unresectable Melanoma, Acral Melanoma","enrollment":17}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral"},"crossReferences":{"chemblId":"CHEMBL4297771"},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":313030,"therapeuticAreas":["Other"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Interleukin","genericName":"Interleukin","companyName":"University of Arkansas","companyId":"university-of-arkansas","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T02:17:44.694254+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}